Vaccine offers new control options for FMD
A new vaccine, developed in the USA, holds promise for
protection against Foot-and-Mouth Disease (FMD).
The vaccine is developed by scientists with the US Department of
Agriculture's Agricultural Research Service (ARS), the Department of Homeland
Security (DHS) and a US biopharmaceutical
The new vaccine works quickly,
demonstrating effectiveness within seven days. Tests thus far have shown that
vaccinated cattle retain immunity for at least 21 days, but scientists expect
that future studies will show that the new vaccine at least matches the six
months of immunity provided by current vaccines.
The new vaccine has
been tested on cattle and swine, and is equally effective in both
"This signals tremendous
promise," said ARS Administrator Edward B. Knipling. "Although this is still an
experimental vaccine, it has made significant developmental progress, and we are
optimistic about its prospects."
Significantly, as this is the first FMD
vaccine produced in the United States, the federal government can plan
adequate supplies for the veterinary strategic
The vaccine is the first
molecular-based FMD vaccine for cattle, developed by scientists with ARS, the
Department of Homeland Security's Targeted Advanced Development unit (TAD) and
GenVec, a biopharmaceutical company based in Gaithersburg, Maryland.
Additional testing is examining the vaccine's commercial viability
and effectiveness against the various serotypes of FMD
The new vaccine has many benefits. It is
administered in a nonreplicating adenovirus. It does not require expensive,
high-containment production facilities, and it can be produced safely in the
United States because it can be made without using infectious FMD
In addition, the vaccine also makes it possible for
scientists to determine whether an animal found to have FMD antibodies acquired
them through vaccination or from infection--an important piece of information
because of the trade restrictions associated with using current
The results of this research effort
will be presented on June 2, at the 2007 American Society for Gene Therapy
meeting in Seattle, Washington, by Douglas E. Brough, senior director of
GenVec's Vector Sciences.
The DHS TAD unit collaborates with ARS and
industry to develop vaccines and biotherapeutic medication for the US Department
of Agriculture. ARS is USDA's principal intramural scientific research
â€¢ Agricultural Research Service (ARS)
â€¢ United States Department of Agriculture (USDA)
the latest pig news, subscribe here
To comment, login here
Or register to be able to comment.